Literature DB >> 28939068

Appraisal of the AJCC 8th edition pathologic staging modifications for HPV-positive oropharyngeal cancer, a study of the National Cancer Data Base.

Kevin Y Zhan1, Antoine Eskander2, Stephen Y Kang1, Matthew O Old1, Enver Ozer1, Amit A Agrawal1, Ricardo L Carrau1, James W Rocco1, Theodoros N Teknos3.   

Abstract

BACKGROUND: The American Joint Commission on Cancer (AJCC) recently created new staging for human papillomavirus associated oropharyngeal cancer (HPV+ OPSCC) for its 8th edition. These proposals have not yet been validated in a national registry.
METHODS: Review of National Cancer Database (NCDB) for surgically-treated HPV+ OPSCC for years 2010-2014 to validate the new staging system using the Kaplan Meier method to explore survival outcomes.
RESULTS: 3745 cases were analyzed. Median follow-up was 31.3months. Most patients were Caucasian males with tonsillar cancer. Distribution of stage I disease increased from 3.7% to 80.2% in AJCC 8th. pN1 disease shifted from 17.3% to 75.9%. Treatment and distribution of T-stage varied by pathologic nodal (pN) staging. Extranodal extension (ENE) was positive in 41% cases. Four-year overall survival (OS) for AJCC 8th stages I (92%), II (81%), and stage III (62%) showed excellent hazard discrimination (all pairwise p<0.001). Only 4-year OS by pN staging showed significantly different curves when comparing pN2 (79%) with others (pN0 88%; pN1 91%, p=0.01 and <0.001 respectively). Presence of ENE confers a negative effect on overall survival (92% ENE- vs. 85% ENE+, p<0.001).
CONCLUSION: The NCDB shows improved hazard discrimination and outcome prediction in the AJCC 8th edition staging for HPV+ OPSCC. While overall staging had excellent hazard discrimination, this accounted for poorer discrimination between pN0 and pN1. The majority of patients are reclassified as overall stage I. Presence of extranodal extension demonstrated a statistically significant but modest negative effect on overall survival. CONDENSED ABSTRACT (2 SENTENCES): Using NCDB data for validation, the AJCC 8th ed. pathologic staging system offers much improved hazard discrimination and prognostication in HPV oropharyngeal cancer, with the majority of cases reclassified as pStage I. Of note, only pN2 offered hazard discrimination within nodal staging and presence of pathologic extranodal extension has a modest negative effect on survival.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  AJCC; Base of tongue cancer; Extranodal extension; HPV; Head and neck cancer; NCDB; Oropharynx cancer; Staging; Tonsil cancer; p16

Mesh:

Year:  2017        PMID: 28939068     DOI: 10.1016/j.oraloncology.2017.08.020

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  17 in total

1.  The 8th edition AJCC/UICC TNM staging for p16-positive oropharyngeal carcinoma: is there space for improvement?

Authors:  Shachi Jenny Sharma; Steffen Wagner; Henrike Simone Frauke Reder; Tobias Kroll; Nora Wuerdemann; Jens Peter Klussmann; Claus Wittekindt
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-10-16       Impact factor: 2.503

2.  Acoustofluidic Salivary Exosome Isolation: A Liquid Biopsy Compatible Approach for Human Papillomavirus-Associated Oropharyngeal Cancer Detection.

Authors:  Zeyu Wang; Feng Li; Joseph Rufo; Chuyi Chen; Shujie Yang; Liang Li; Jinxin Zhang; Jordan Cheng; Yong Kim; Mengxi Wu; Elliot Abemayor; Michael Tu; David Chia; Rachel Spruce; Nikolaos Batis; Hisham Mehanna; David T W Wong; Tony Jun Huang
Journal:  J Mol Diagn       Date:  2020-01       Impact factor: 5.568

3.  The diagnostic performance of CT and MRI for detecting extranodal extension in patients with head and neck squamous cell carcinoma: a systematic review and diagnostic meta-analysis.

Authors:  Sang Ik Park; Jeffrey P Guenette; Chong Hyun Suh; Glenn J Hanna; Sae Rom Chung; Jung Hwan Baek; Jeong Hyun Lee; Young Jun Choi
Journal:  Eur Radiol       Date:  2020-09-19       Impact factor: 5.315

4.  Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials.

Authors:  Carole Fakhry; Qiang Zhang; Maura L Gillison; Phuc Felix Nguyen-Tân; David I Rosenthal; Randal S Weber; Louise Lambert; Andy M Trotti; William L Barrett; Wade L Thorstad; Sue S Yom; Stuart J Wong; John A Ridge; Shyam S D Rao; Sharon Spencer; Andre Fortin; David Raben; Jonathan Harris; Quynh-Thu Le
Journal:  Cancer       Date:  2019-03-26       Impact factor: 6.860

Review 5.  Robotic vs. transoral laser surgery of malignant oropharyngeal tumors-what is best for the patient? : A contemporary review.

Authors:  Thomas H Nagel; Brent A Chang; Michael L Hinni
Journal:  HNO       Date:  2022-04-13       Impact factor: 1.284

Review 6.  Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions.

Authors:  Elaine O Bigelow; Tanguy Y Seiwert; Carole Fakhry
Journal:  Oral Oncol       Date:  2020-04-02       Impact factor: 5.337

7.  Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI.

Authors:  Aimée R Kreimer; Anil K Chaturvedi; Laia Alemany; Devasena Anantharaman; Freddie Bray; Mary Carrington; John Doorbar; Gypsyamber D'Souza; Carole Fakhry; Robert L Ferris; Maura Gillison; D Neil Hayes; Allan Hildesheim; Shao Hui Huang; Luiz P Kowalski; Krystle A Lang Kuhs; James Lewis; Douglas R Lowy; Hisham Mehanna; Andy Ness; Michael Pawlita; Maisa Pinheiro; John Schiller; Meredith S Shiels; Joseph Tota; Lisa Mirabello; Saman Warnakulasuriya; Tim Waterboer; William Westra; Stephen Chanock; Paul Brennan
Journal:  Oral Oncol       Date:  2020-06-02       Impact factor: 5.337

8.  Treatment trends in oropharyngeal carcinoma: Surgical technology meets the epidemic.

Authors:  T J Gal; Jon A Slezak; Alexandra E Kejner; Quan Chen; Bin Huang
Journal:  Oral Oncol       Date:  2019-08-14       Impact factor: 5.972

9.  Disparities and guideline adherence for HPV testing among patients with oropharyngeal squamous cell carcinoma, NCDB, and SEER.

Authors:  Solomon Husain; Shivangi Lohia; Valentina Petkov; Timothy Blackwell; Samuel Swisher-McClure; Aviram Mizrachi; Luc G Morris; Marc A Cohen; Richard J Wong; Benjamin R Roman
Journal:  Head Neck       Date:  2021-04-13       Impact factor: 3.821

10.  Genomic heterogeneity and copy number variant burden are associated with poor recurrence-free survival and 11q loss in human papillomavirus-positive squamous cell carcinoma of the oropharynx.

Authors:  Travis P Schrank; Nicholas Lenze; Lee P Landess; Alan Hoyle; Joel Parker; Asim Lal; Siddharth Sheth; Bhishamjit S Chera; Samip N Patel; Trevor G Hackman; M Ben Major; Natalia Issaeva; Wendell G Yarbrough
Journal:  Cancer       Date:  2021-04-05       Impact factor: 6.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.